Lupin Limited

rs,

August 4, 2023 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Band

32%

n meaningful and profitable growth Key Metrics Business Performance INR mn 47,421 mn Revenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margi

10%

ful and profitable growth Key Metrics Business Performance INR mn 47,421 mn Revenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ

18.5%

Key Metrics Business Performance INR mn 47,421 mn Revenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 1

269%

usiness Performance INR mn 47,421 mn Revenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth

43%

rformance INR mn 47,421 mn Revenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets

9.5%

evenue 32% YoY 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North

5%

Y 10% QoQ 8,791 mn EBITDA1 18.5% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North America 15,

11%

% Margin 269% YoY 43% QoQ 4,523 mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North America 15,905 mn 57% YoY 3% QoQ EMEA 3,987

4%

mn Net Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North America 15,905 mn 57% YoY 3% QoQ EMEA 3,987 mn 20% YoY 12% QoQ API 3,371

7%

Income 9.5% margin 5% QoQ India 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North America 15,905 mn 57% YoY 3% QoQ EMEA 3,987 mn 20% YoY 12% QoQ API 3,371 mn ROW

57%

ndia 16,384 mn 10% YoY 11% QoQ Growth Markets 4,066 mn 4% YoY 7% QoQ North America 15,905 mn 57% YoY 3% QoQ EMEA 3,987 mn 20% YoY 12% QoQ API 3,371 mn ROW 1,656 mn 32% YoY 5% QoQ 85% Yo

“60% of the hazardous waste generated in its Indian operations will be sent to cement plants for co-processing by 2025.”

Note

2

Note

1. 2. IQVIA Qtr Gx Jun-23 by prescriptions iQVIA Qtr Mar-23 NSP data Evolving Complex Product Portfolio through investments in Injectables and Inhalation • Current pipeline includes 54 FTFs incl. 21 exclusive FTFs • Substantial investments in Inhalation, Injectables and Biosimilars pipeline and capabilities (Development and Manufacturing) • 30+ strong pipeline of Injectables and 22+ strong inhalation pipeline 7 07 Other Markets: Key Highlights Other Key Markets driving growth Emerging Markets: Steady growth EU • Luforbec, Namuscla and levetiracetam growing • Completed Medisol acquisition in France Brazil • BRL 75 mn sales in Q1 FY24 (growth of 30% YoY) driven by ibuprofen & acquired portfolio In reference market, ranks 2nd3 • South Africa • • 8th largest generics player1 5% YoY growth to reach ZAR 295 mn sales in Q1 FY24 Mexico • Recorded 59% YoY decline with MXN 86.2 Mn, due to impact of stock- outs Australia • • 4th largest generics player2 SCP acquisition performing well Philippines

Note

1. IQVIA May 23 by sales 2. IQVIA Midas Sales Audit Mar-23 • API revenues grew 32% YoY in Q1 FY24 due to core API business growth ​ • Continued leadership in anti-TB Institutional business and increasing ARV registrations 3. IQVIA MAT May-23 8 Key Financial Metrics: Quarterly Trend 3,900 3,600 3,300 3,000 2,700 2,400 2,100 1,800 1,500 1,200 900 600 300 0 R&D (INR mn) 2,000 3,376 2,896 3,050 3,679 15.0% 13.0% 1,500 11.0% Capex (INR mn) 1,540 1,555 1,502 8.3% 6.8% 7.0% 7.8% 1,000 500 3.8% 3.7% 3.5% 9.0% 7.0% 5.0% 3.0% 1.0% -1.0% 0 10.0% 9.0% 8.0% 7.0% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0% 1,171 2.6% Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 R&D (INR Mn) R&D (% of Sales) Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Capex (INR Mn) Capex % of Sales Net debt/ Equity 0.27 0.25 0.20 0.10 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 9 P&L Highlights Q1 FY24 Amount in INR mn Q1FY24 % of Sales Q4FY23 % of Sales QoQ Growth Q1FY23 % of Sales YoY Growth Sales 47,421 100.0% 43,303 100.0% 9.5% 36,040 100.0% 31.6% Other operating income 719